02nd week of 2009 patent applcation highlights part 36 |
Patent application number | Title | Published |
20090010809 | MANUAL PIPETTE FILLER - A pipette device for aspirating and dispensing liquid, the pipette device comprising: a housing including a handgrip portion; and a bulb contained within the handgrip portion of the housing, the bulb compressible by a user to facilitate aspirating and dispensing of liquid. | 2009-01-08 |
20090010810 | PRECISION LIQUID DISPENSING SYSTEM - A system for dispensing microdrops of reagent in small, precisely metered quantities maintains the fluid reagent to be dispensed in a reservoir under a controlled pressure. The reagent is dispensed through multiple nozzles connected to solenoid-actuated valves that control the flow of the reagent from the reservoir to the nozzles. Each valve is connected to one of the nozzles and electrical pulses are supplied separately to each of the valves to separately control the opening and closing of each valve to dispense predetermined quantities of the reagent through each nozzle at predetermined times. | 2009-01-08 |
20090010811 | System for Selective Illumination of Well Plates - An illumination system enhances a manual human process associated with a multiwell plate having an array of wells thereon. The illumination system includes a compact self-contained apparatus including an illuminator coupled to a human interface. The human interface is configured to receive an operating parameter input and a start input. The illuminator has a protective surface for receiving the well plate and a plurality of underlying light sources configured to initiate a sequence of different well subarray indications in response to the start input and pursuant to the operating parameter input. | 2009-01-08 |
20090010812 | APPARATUS AND MEANS FOR CONTROLLING TEMPERATURE DURING LIQUID PURIFICATION - An apparatus and means for separating an ultraviolet light source from a liquid and for controlling the temperature of the ultraviolet light source to its optimal temperature range for modifying contaminants in a liquid. | 2009-01-08 |
20090010813 | Air Freshener - An air freshener of the invention includes a rotating box, a fixed base disposed on the rotating box, the rotating box rotating with respect to the fixed base, and a perfume box filled with a perfume, which can rotate with the rotating box. The rotating box has an annular shape in cross section and has an internal space for receiving and embedding the perfume box therein. Air holes are formed in the fixed base for exposing a portion of the perfume box when the rotating box is rotated with respect to the fixed base. The air freshener of the invention is applicable to be used inside a car or a room, and is capable of both refreshing the air and adjusting the release amount of the diffused perfume vapor. | 2009-01-08 |
20090010814 | EFFLUENT GAS STREAM TREATMENT SYSTEM HAVING UTILITY FOR OXIDATION TREATMENT OF SEMICONDUCTOR MANUFACTURING EFFLUENT GASES - An effluent gas stream treatment system for treatment of gaseous effluents such as waste gases from semiconductor manufacturing operations. The effluent gas stream treatment system comprises a pre-oxidation treatment unit, which may for example comprise a scrubber, an oxidation unit such an electrothermal oxidizer, and a post-oxidation treatment unit, such as a wet or dry scrubber. The effluent gas stream treatment system of the invention may utilize an integrated oxidizer, quench and wet scrubber assembly, for abatement of hazardous or otherwise undesired components from the effluent gas stream. Gas or liquid shrouding of gas streams in the treatment system may be provided by high efficiency inlet structures. | 2009-01-08 |
20090010815 | HEXAGONAL-CELL HONEYCOMB CATALYZER FOR PURIFYING EXHAUST GAS - A hexagonal-cell honeycomb catalyzer is for purifying an exhaust gas. The catalyzer comprising a support that has a plurality of cells and a purification layer that has an HC absorption layer and a three-way catalyst layer. The HC absorption layer is formed on the honeycomb-formed surface of each wall of the support. The three-way catalyst layer is formed on the surface of the HC absorption layer. Provided that the HC absorption layer has a thickness a | 2009-01-08 |
20090010816 | APPARATUS AND METHOD FOR CONTROLLED COMBUSTION OF GASEOUS POLLUTANTS - The present invention relates to systems and methods for controlled combustion of gaseous pollutants while reducing and removing deposition of unwanted reaction products from within the treatment systems. The systems employ a two-stage thermal reactor having an upper thermal reactor including at least one inlet for mixing a gaseous waste stream with oxidants and combustible fuels for thermal combustion within the upper thermal reactor. The upper thermal reactor further includes a double wall structure having an outer exterior wall and an interior porous wall that defines an interior space for holding a fluid and ejecting same, in a pulsating mode, through the interior porous wall into the upper thermal reactor to reduce deposition of the reaction products on the interior of the upper reactor chamber. The two-stage thermal reactor further includes a lower reactor chamber for flowing reaction products formed in the upper thermal reactor through a water vortex that provides a water overflow along the interior of the lower reactor chamber thereby reducing deposition of unwanted products on the interior surface of the lower reactor. | 2009-01-08 |
20090010817 | Honeycomb filter - A honeycomb filter according to the present invention is composed of multiple segments each having a large number of through holes, which are separated from each other by porous bulkheads as running through in an axis direction of the segment, the segments bonded with each other by a bonding material. In the honeycomb filter, a heat capacity of the segments arranged in the peripheral portion is higher than that of the segments arranged in the center portion. | 2009-01-08 |
20090010818 | Atmospheric Pressure Plasma Generating Apparatus by Induction Electrode - The present invention relates to an atmospheric pressure plasma generating apparatus using an induction electrode. In particular, one or more upper metal electrodes are disposed on the upper side and an induction electrode and an induction electrode antenna are disposed opposite to the upper electrodes, so that a high-density plasma is generated at low applied voltage. Further, base electrodes are used to preclude interference between the upper electrodes. Thus, lots of the upper electrodes can be constructed at a narrow space, the uniformity of intensity of a generated plasma can be secured, the source of a plasma can be provided by the upper electrodes, and the intensity of a plasma can be increased. In addition, a lower electrode is disposed on the lower side in order to extend the length of a generated plasma. | 2009-01-08 |
20090010819 | VERSATILE FLOW PATH - A flow path comprising a reaction cavity in which there is a solid phase to which an affinity reactant I1 has been immobilized by the use of an immobilizing pair of reactive structures that comprises a) a plurality of functional equal structures RSsp on the solid phase, and b) a structure RSari on affinity reactant I1, where RSsp and RSari are mutually reactive with each other to the formation of a link structure that immobilizes affinity reactant I1 to the solid phase. The characteristic feature is that the solid phase comprises a plurality of structures that derive from RSsp but do not immobilize affinity reactant I1 to the solid phase. | 2009-01-08 |
20090010820 | Micro-Fluidic System - In one aspect, a micro-fluidic system consisting of modules that are arranged side by side in a row, each module containing a micro-fluidic unit and an associated electric control unit is provided. The rear faces of the modules lie against a common vertical rear wall unit and are held against the unit. In the modules, the respective control unit is located in the vicinity of the rear face and the micro-fluidic unit is situated in a region that is remote from the rear face. The control units can be connected to an electric line bus that runs through the rear wall unit via electric connectors that are located on the rear faces of the modules and on the rear wall unit and the micro-fluidic units of two respective neighboring modules are interconnected to allow the passage of fluid via a connecting part that contains connection channels and that spans the relevant modules. | 2009-01-08 |
20090010821 | TUBE BUNDLE REACTORS WITH PRESSURE FLUID COOLING - A set of prefabricated tube bundle reactor subassemblies is proposed which are adapted to be assembled at a construction site to provide a tube bundle reactor for carrying out catalytic gas and/or liquid phase reactions. In accordance with the invention, the reactor shell and the reactor heads, on the one hand, and the tube bundle and the tube sheets, on the other hand, form separate subassemblies, more specifically at least one shell/head subassembly, at least one head subassembly, and at least one tube bundle subassembly. The subassemblies comprise means for vertically supporting the tube bundle subassembly and for pressure tightly connecting the shell/head subassembly to the tube sheets without requiring heat treatment during assembly of the subassemblies. Likewise proposed are a tube bundle reactor for carrying out catalytic gas and/or liquid phase reactions and an arrangement of the kind of tube bundle reactors mentioned. | 2009-01-08 |
20090010822 | APPARATUS FOR THE PRODUCTION OF CARBON NANOTUBES - A reactor for preparing carbon nanotubes comprising a reaction chamber, at least one support means located within said reaction chamber capable of supporting a substrate, said substrate being capable of supporting carbon nanotube growth, at least one heating element located within said reaction chamber capable of providing localized heating to said substrate within said reaction chamber, and means for passing a gaseous carbonaceous material into said reaction chamber such that is passes over the contacts said substrate. | 2009-01-08 |
20090010823 | Catalysts, in microchannel apparatus, and reactions using same - The present invention provides new microreactor systems, catalysts, and chemical processes. Methods of making novel catalysts and reaction apparatus are also described. | 2009-01-08 |
20090010824 | DECONTAMINATION SYSTEM - A decontamination pad includes an adsorptive/absorptive knitted activated-carbon layer exposed on a first surface, an activated-carbon fabric attached to the other surface of the knitted layer and backed up an impermeable layer. The activated carbon is saturated with a non-hazardous CWA decontamination solvent as nonspecific means of decontaminating equipment and open-wounds is provided. The pad is packaged in a sealed, disposable plastic packet. The pad is thus a simple and immediate means of personal decontamination by applying the exposed surface of the knitted layer to the surface to be decontaminated. | 2009-01-08 |
20090010825 | Steam Delivery Device - Steam delivery device comprising a nozzle ( | 2009-01-08 |
20090010826 | Toothbrush Sterilizer - A toothbrush sterilizer is provided. The toothbrush sterilizer employs a magnet on its pivoting cover and a lead switch on its main body opposite the cover to illuminate its sterilizing lamp only when the cover is closed, has a detachable toothbrush storage compartment, has a lamp holder that allows easy replacement of the sterilizing lamp and a detachably mounted stand with a water receiving area, and is easy to use and maintain in a hygienic state. The toothbrush sterilizer includes a storage compartment detachably attached inside the main body. The storage compartment has a plate, a side wall erected around a perimeter of the plate, and a plurality of insert holes formed in and extending a predetermined distance down from the plate, for storing the toothbrushes therein. | 2009-01-08 |
20090010827 | Process for Sequestration of Carbon Dioxide - A process for sequestration of carbon dioxide comprising the following steps: (a) dispersing solid waste material comprising calcium oxide and a calcium-comprising mixed oxide in water to dissolve at least part of the calcium oxide and to form calcium oxide-depleted solid waste material in a calcium hydroxide solution; (b) separating the calcium hydroxide solution from the calcium oxide-depleted solid waste material; (c) converting the calcium hydroxide in the separated calcium hydroxide solution in precipitated calcium carbonate; and (d) contacting an aqueous slurry of the calcium oxide-depleted solid waste material with carbon dioxide for mineral carbonation of the carbon dioxide to form carbonated solid waste material. | 2009-01-08 |
20090010828 | MERCURY CONTROL USING MODERATE-TEMPERATURE DISSOCIATION OF HALOGEN COMPOUNDS - A system and method is provided for the removal of mercury from flue gas. Effective removal of mercury is obtained by oxidation of elemental mercury, with highly reactive halogen species derived from dissociation of halogen compounds at moderate temperatures brought into contact with the flue gas with or without the addition of carbon. | 2009-01-08 |
20090010829 | Reducing Agent Composition - The invention relates to a reducing agent composition for use in the catalytic reduction process of nitrogen oxides in exhaust gases, the composition containing 20-40 w % of urea, 19-40 w % of ammonium formate, and water. | 2009-01-08 |
20090010830 | High quantum yield white phosphors and methods of making - Embodiments of the present disclosure include a composition comprising a Gd | 2009-01-08 |
20090010831 | Negative Active Material For a Rechargeable Lithium Battery, a Method of Preparing the Same, and a Rechargeable Lithium Battery Comprising the Same - The negative active material for a rechargeable lithium battery of the present invention includes a carbonaceous material and a silicon-based compound represented by Formula 1: | 2009-01-08 |
20090010832 | PROCESS FOR THE PREPARATION OF FINELY DIVIDED PRECIPITATED SILICA - The present invention provides a process for the preparation of finely divided precipitated silica. Finely divided precipitated silica is prepared by neutralization of alkali silicate solution, under continuous stirring, at 60° to 90° C. in presence of alkali metal salt as coagulating agent, in various neutralization steps during which neutralization is interrupted for specific time. Further acidic silica sol, is added until 60 to 80% of total alkali is neutralized. The reaction mixture is then aged at least for 3 minute under continuous agitation, followed by circulation through centrifugal pump at an appropriate rate. | 2009-01-08 |
20090010833 | PROCESS FOR PRODUCING ULTRA-FINE POWDER OF CRYSTALLINE SILICON - A method of producing a fine powder of crystalline silicon. | 2009-01-08 |
20090010834 | Process for the Thermal Reduction of Sulfur Dioxide to Sulfur - Processes for the thermal reduction of sulfur dioxide to elemental sulfur are described and disclosed. The processes described include three general reaction sections, including the reaction furnace portion where the SO | 2009-01-08 |
20090010835 | Systems and methods for generating and storing ozone - Devices for generating and storing ozone. The device includes a tank for containing gas therein; an ozone generator for generating ozone and communicating the ozone with the tank; and at least one valve for admitting gas into the device, holding gas in the device, and discharging gas from the device. | 2009-01-08 |
20090010836 | HYDROGEN STORAGE MATERIALS, METAL HYDRIDES AND COMPLEX HYDRIDES PREPARED USING LOW-BOILING-POINT SOLVENTS - The invention provides systems and methods for preparing hydrogen storage materials using low boiling point solvents or reaction media. Examples of such solvents or reaction media include dimethyl ether, ethyl methyl ether, epoxyethane, and trimethylamine. The synthesis of the hydrogen storage materials is conducted is a selected medium, and after synthesis is complete, the reaction medium is removed as necessary by moderate heating. | 2009-01-08 |
20090010837 | Hydrogen Generation Apparatus, Laser Reduction Apparatus, Energy Conversion Apparatus, Hydrogen Generation Method and Electric Power Generation System - Object: To provide a hydrogen generation apparatus, a laser reduction apparatus, an energy conversion apparatus, a hydrogen generation method and an electric power generation system. | 2009-01-08 |
20090010838 | Pyridylacetylenes for Use as Radiotracers and Imaging Agents - The present invention relates to novel pyridylacetylene derivatives of formula I | 2009-01-08 |
20090010839 | Avidin dimers effective in increasing the concentration of radioactive biotin in pretargeted radioimmunotherapy - Dimers of avidin and streptavidins (diavidins) are described wherein the linker is suberate, which in turn, is bound to different functional groups (—NH2 o-COOH) of avidin. As compared to avidin, the diavidins have shown the ability to increase the amount of labelled biotin on the target, when used in an in vitro pretargeting test using supported human tenascin, the biotinylated anti-tenascin monoclonal antibody (Mab-B), avidin/diavidin, and biotin- | 2009-01-08 |
20090010840 | BISPECIFIC SINGLE CHAIN Fv ANTIBODY MOLECULES AND METHODS OF USE THEREOF - Bispecific single chain antibody molecules are disclosed which may be used to advantage to treat various forms of cancer associated with the overexpression of members of the EGFR protein family. | 2009-01-08 |
20090010841 | PROSTATE CANCER SPECIFIC INTERNALIZING HUMAN ANTIBODIES - This invention provides novel prostate cancer specific internalizing human antibodies. The antibodies are useful by themselves to prevent growth and/or proliferation of prostate cancer cells. The antibodies can also be formulated as chimeric molecules to direct an effector (e.g. a cytotoxin, an imaging reagent, a drug, etc.) to a prostate tumor site. | 2009-01-08 |
20090010842 | Methods for the early diagnosis of ovarian cancer - The present invention discloses the protease stratum corneum chymotryptic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these peptides in monitoring and the development of immunotherapies for ovarian and other malignancies. | 2009-01-08 |
20090010843 | Methods of Identifying Antibodies to Ligands of Orphan Receptors - Described is a method of identifying antibodies against hitherto unknown ligands of orphan receptors or other orphan ligands, i.e., receptors or other ligands where the counter-ligand has not yet been identified. The availability of antibodies binding to the unknown ligand significantly facilitates their isolation and characterization, and the identified antibodies can themselves be useful for treating patients with cancer or autoimmune diseases, or other disorders. An exemplary embodiment provides for a method designated Identification of Therapeutic Antibodies by Competitive Screening (ITACS). Described are also fusion proteins comprising a soluble portion of an orphan receptor, such as NKp30, and the Fc portion of an antibody. The fusion proteins typically comprise a Flexible Transmembrane Linker (FTL), i.e., a linker comprising a portion of a transmembrane domain of the orphan receptor. | 2009-01-08 |
20090010844 | Imaging Infection With Compounds That Bind to Thymidine Kinase - The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection. | 2009-01-08 |
20090010845 | Polybiotin Compounds of Magnetic Resonance Imaging and Drug Delivery - The invention relates generally to biotin-containing compounds that are useful as imaging agents and drug-delivery agents. Another aspect of the invention relates to the aforementioned compounds chelated to a metal atom. In a preferred embodiment, the metal atom is a gadolinium. Another aspect of the invention relates to a compound comprising three biotin moieties and a pharmaceutical agent covalently bound to a heterocyclic core. In certain embodiments, the pharmaceutical agent is an antibiotic, antiviral, or radionuclide. Another aspect of the present invention relates to a method of treating disease involving administering the compounds of the invention to a mammal. Another aspect of the present invention relates to a method of acquiring a magnetic resonance image using the compounds of the invention. | 2009-01-08 |
20090010846 | Nitro-Imidazole Hypoxia Imaging Agents - The present invention relates to novel radioactively labeled bioreducible tracers of Formula I useful for detecting hypoxic tumors or ischemic tissue in vivo. In one embodiment, the tracers consist of a 2-nitroimidazole moiety, a triazole, metabolically stable linker with pharmacokinetics enhancing substituents, and a radioisotope. The preferred in vivo imaging modality is positron emission tomography. | 2009-01-08 |
20090010847 | Connective Tissue Growth Factor-4 - The present invention relates to a novel human protein called Connective Tissue Growth Factor-4, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein. | 2009-01-08 |
20090010848 | Recombinant Peptides Derived from the Mc3 Anti-BA46 Antibody, Methods of Use Thereof, and Methods of Humanizing Antibody Peptides - The present invention provides recombinant peptides that specifically and selectively bind to the human milk fat globule (HMFG) antigen, BA46. In particular, the present invention provides recombinant variants of the Mc3 antibody, including humanized versions of Mc3. The variant Mc3 peptides are particularly useful for diagnostic, prognostic, and therapeutic applications in the field of breast cancer. | 2009-01-08 |
20090010849 | Methods of screening an agent for an activity in an isolated eye of a teleost - The present invention provides methods of screening an agent for an activity in an isolated organ, e.g., eye, from a teleost, e.g., zebrafish. Methods of isolating eyes from zebrafish are provided. Methods of screening an agent for an ocular activity in the isolated eye are provided. Methods of screening an agent for an ocular activity in a model of ocular disease or disorder are provided. Methods of screening an agent for an ocular activity in the isolated eye and for screening the agent for cell death and/or toxic activity in the eye or other organ or tissue are provided. The invention further provides high throughput methods of screening agents for an activity in isolated eyes of zebrafish in multi-well plates. | 2009-01-08 |
20090010850 | Formulations and methods for treating dry eye - The present invention provides compositions for treating and/or preventing signs and symptoms associated with dry eye and/or ocular irritation, and methods of use thereof. Such compositions are provided in novel ophthalmic formulations that are comfortable upon instillation in the eye. | 2009-01-08 |
20090010851 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function - The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X | 2009-01-08 |
20090010852 | PROCESS AND APPARATUS FOR PREPARING A DIAGNOSTIC OR THERAPEUTIC AGENT - Provided are a preparation process of a diagnostic or therapeutic agent having a step of adding, to a first fine emulsion having a particle size of 0.5 μm or less prepared by applying a predetermined pressure to a first mixture containing a first hydrophobic compound, an emulsifying agent, and an aqueous phase, a second hydrophobic compound compatible with the first hydrophobic compound, thereby preparing a second mixture; and a step of stirring and shaking the second mixture in a hermetically sealed state, thereby embedding the second hydrophobic compound in the first fine emulsion to prepare a second fine emulsion having a particle size of 0.5 μm or less; a diagnostic or therapeutic agent prepared by the process; and an apparatus for carrying out the process. | 2009-01-08 |
20090010853 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds. | 2009-01-08 |
20090010854 | Pulmonary insulin crystals - The present invention provides methods and compositions for treating diabetes by administering acylated insulin or an acylated insulin analog via a pulmonary route. The insulin or insulin analog may be in the form of a dry powder or a solution. | 2009-01-08 |
20090010855 | Cationic Polymers And Fixative Applications Therefor - This invention relates to cationic | 2009-01-08 |
20090010856 | Composition, Comprising Hydrofluoric Acid, for Inhibiting Dental Erosion - The present invention relates to a composition, for inhibiting dental erosion, and the use thereof. The composition comprises an aqueous solution of hydrofluoric acid, in which the concentration of hydrofluoric acid is 0.05%-2.00% and the pH is between 2.5 and 4.5. | 2009-01-08 |
20090010857 | Toothpaste Comprising Calcium Carbonate and Zinc Citrate - Toothpaste and method for making such, the toothpaste comprising calcium carbonate as abrasive, water and zinc salt substantially all of which is in the form of water-solubilised zinc citrate. | 2009-01-08 |
20090010858 | Oral cavity disinfectant and oral cavity disinfecting method - Provided is an oral cavity disinfectant prepared by using a mixed aqueous solution containing a substance for dissolving proteins deposited on the tooth surface to sterilize microbes and a calcium salt-precipitating substance, respectively, at predetermined concentrations, that can be used to remove the bio film easily in a manner similar to tooth brushing. Thus, in a first embodiment of the present invention, an oral cavity disinfectant for the removal of microbes deposited on the enamel formed on the tooth surface is provided. The oral cavity disinfectant is a mixed aqueous solution containing a protein-dissolving substance dissolving proteins deposited on the enamel surface and a calcium salt-precipitating substance, respectively, at predetermined concentrations. | 2009-01-08 |
20090010859 | Oral Composition - A visually clear gel toothpaste composition comprising a sparingly soluble divalent metal salt, characterised in that the sparingly soluble divalent metal salt is fully solubilised by a chelating agent for the metal salt, the chelating agent having a log Ks1 for the divalent metal ion as herein defined of from 3.0 to 7.0. | 2009-01-08 |
20090010860 | Merocyanine Derivatives - Disclosed is the use of the compounds of formula | 2009-01-08 |
20090010861 | Modified Plant Gums for Preparations of Active Ingredients - The present invention relates to compositions containing (fat-soluble) active ingredients and/or colorants in a matrix based on modified plant gums, i.e. plant gums that have been submitted to hydrolysis to degrade either the protein portion and/or where appropriate, the polysaccharide, and to a process for preparing these compositions as well as to modified plant gums, whose protein part is hydrolysed up to a degree of about 30%, preferably to a degree of from about 0.05 to about 30%, and/or whose polysaccharide part is hydrolysed up to a degree of about 50%, a process for the manufacture thereof and such modified plant gums themselves. The present invention further relates to the use of the compositions of this invention for the enrichment, fortification and/or for the coloration of food, beverages, animal feed, cosmetics and pharmaceutical compositions and to such food, beverages, animal feed, cosmetics and pharmaceutical compositions themselves. | 2009-01-08 |
20090010862 | FOAMING OIL COMPOSITIONS - A personal care composition comprising an oil and a siloxane resin foam stabilizer, said composition being substantially free of surfactants and propellants, is provided. The composition is capable of foaming, and is advantageously clear and non-greasy. | 2009-01-08 |
20090010863 | Cosmetic Compositions - There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises two or more active ingredients selected from the group consisting of a) dipalmitoyl hydroxyproline, salts and esters thereof; b) carnitine; and c) an extract of | 2009-01-08 |
20090010864 | Low residue deodorant or antiperspirant stick based on an ethanol-containing oil-in-water dispersion/emulsion - Deodorant or antiperspirant sticks based on an ethanol-containing oil-in-water dispersion/emulsion for application on the skin. | 2009-01-08 |
20090010865 | Process for Preparing Polymers in Aqueous Solvents - The present invention relates to methods of producing polymers which comprise, in copolymerized form, 50-95% by weight of at least one ester of (meth)acrylic acid, 5-50% by weight of at least one olefinically unsaturated, free-radically polymerizable anionogenic or anionic compound and 0 to 30% by weight of at least one further free-radically polymerizable compound by free-radical polymerization in an alcohol-comprising solution, where the polymerization initiator used is at least one water-soluble initiator. | 2009-01-08 |
20090010866 | Hair care compositions - The invention provides a hair care composition comprising:
| 2009-01-08 |
20090010867 | Skin Cleansing Composition - To provide a skin cleanser having superior lather quality at cleansing and improved moist and soft feeling after cleansing. A skin cleansing composition comprising an amphoteric terpolymer which consists of, 5 to 15 mass % of an anionic monomer (ex. acrylic acid), 15 to 40 mass % of a cationic monomer (ex. dimethyldiallylammonium chloride) and 45 to 80 mass % of a nonionic monomer (ex. acrylamide). | 2009-01-08 |
20090010868 | COMPOSITION COMBINING A SILICONE POLYMER AND A TACKIFYING RESIN - The present invention relates to a solid composition containing, in a physiologically acceptable medium, at least one fatty phase containing:
| 2009-01-08 |
20090010869 | Compositions for Topical Enzymatic Debridement - Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity, and stability. The formulations, optionally containing non-animal source biologics, may be in the form of lotions, aerosols to provide a spray, or a foam. A non-reactive substrate may be used as a composition carrier. A non-aqueous lotion formulation having improved enzymatic activity is provided. The non-aqueous lotion viscosity is adjusted to achieve high enzymatic activity while maintaining the application benefits of high viscosity non-aqueous lotions. The lotion formulation may be delivered in a patch. | 2009-01-08 |
20090010871 | Method for Production of a Transformed Cell - The invention relates to a method for incorporation of a biomolecule into a cell including the method steps: i) production of a complex from a biomolecule, preferably a nucleic acid and a polymer which may be obtained by reaction of an amine monomer having at least two amine groups with an epoxide monomer having at least two epoxide groups and ii) incorporation of the biomolecule into a cell bx bringing the cell into contact with the complex. The invention further relates to the transformed cell obtained by said method, the use of a particular polymer for incorporation of a biomolecule into a cell, a kit for incorporation of a biomolecule into a cell, the use of said kit, a complex made from a biomolecule and a polymer, a therapeutic composition, the use of a complex of a biomolecule and a polymer for therapeutic treatment of the human or animal being and a method for treatment of a disease by means of gene therapy. | 2009-01-08 |
20090010872 | Chimeric soluble hyper il-11 and use thereof - The present invention concerns a new designer cytokine termed H11, which is constructed by fusion of two soluble components, soluble interleukin 11 receptor (sIL-11 R) and interleukin 11 (IL-11) using their natural sequence and its use for the production of a medicament for treating or preventing a disease selected from the group consisting of a proliferative disease, a cytopathy, radiation damage, an IL-11 dependent inflammatory disorder, IL-11 dependent degenerative disorder and IL-11 dependent or mediated soft tissue disorder. | 2009-01-08 |
20090010873 | Methods of Cell Therapy, Neurogenesis and Oligodendrogenesis - A method is provided for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells, which comprises administering to an individual in need a neuroprotective agent such as a nervous system (NS)-specific antigen, a peptide derived therefrom, T cells activated therewith, poly-YE, microglia activated by IFN-γ and/or IL-4 and combinations thereof. The method includes stem cell therapy in combination with the neuroprotective agent. | 2009-01-08 |
20090010874 | MODIFIED IL-4 MUTEIN RECEPTOR ANTAGONISTS - This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life. | 2009-01-08 |
20090010875 | IL-7 Fusion Proteins - The invention is directed to a fusion protein which includes a first portion including an immunoglobulin (Ig) chain and a second portion including interleukin-7 (IL-7). | 2009-01-08 |
20090010876 | VISFATIN AND USES THEREOF - The invention is directed to methods for treating, inhibiting or prevent the incidence of vascular disease in a subject or in a non-human animal by administering visfatin. Particularly, the invention provides for methods to prevent phagocyte cell death due to ER-stress by the administration of visfatin. The invention also encompasses methods for identifying a visfatin polypeptide or a visfatin nucleic acid capable of treating a vascular disease as well as pharmaceutical compositions comprising visfatin. | 2009-01-08 |
20090010877 | Methods for treatment prostate cancer using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione - Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or avoiding adverse side effects associated with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy which comprise the administration of an immunomodulatory compound. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2009-01-08 |
20090010878 | Pulsatile dosing of gossypol for treatment of disease - This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis. | 2009-01-08 |
20090010879 | Receptor Based Antagonists and Methods of Making and Using - The present invention provides a fusion polypeptide capable of binding a cytokine to form a nonfunctional complex. It also provides a nucleic acid sequence encoding the fusion polypeptide and methods of making and uses for the fusion polypeptide. | 2009-01-08 |
20090010880 | 2-Amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranosyl Inhibitors of Positive Sense Single-Stranded RNA Envelope Viruses - The present invention is directed to compounds, compositions and methods comprising the aminoglycoside moiety represented by Formula II for treating and preventing the spread of positive sense single-stranded RNA envelope viral infections. One embodiment of the present invention uses geneticin or its analogs, including 2-amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranose, as the antiviral agent. The compounds, compositions and methods of the present invention are applicable to infections resulting from Hepatitis C virus, West Nile virus, Yellow Fever virus, Dengue virus, Bovine Viral Diarrhea virus, Equine Arteritis virus, and/or Sindbis virus. | 2009-01-08 |
20090010881 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2009-01-08 |
20090010882 | POLYMORPHS OF SODIUM 4-4[(4-CHLORO-2-HYDROXYBENZOYL) AMINO] BUTANOATE - The present invention relates to amorphous and polymorphic forms of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate and their use for facilitating the delivery of active agents, such as insulin, to a target. | 2009-01-08 |
20090010883 | TREATMENT WITH ANTI-VEGF ANTIBODIES - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2009-01-08 |
20090010884 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION - The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents. | 2009-01-08 |
20090010885 | Methods for Detecting and Treating Autoimmune Disorders - The present disclosure relates to methods for inhibiting an autoimmune disease by administering to a subject a therapeutically effective amount of a composition that increases FOXP3 expression, thereby inhibiting the autoimmune disease. Further disclosed herein are methods for detecting in a subject an autoimmune disease or a predisposition to an autoimmune disease, and methods for assessing the efficacy of a therapy for an autoimmune disease. | 2009-01-08 |
20090010886 | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione - Methods of treating, preventing and/or managing a myeloproliferative disease are disclosed. Specific methods encompass the administration of a selective cytokine inhibitory drug, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof, alone or in combination with a second active agent, and/or the transplantation of blood or cells. Particular second active agent is capable of suppressing the overproduction of hematopoietic stem cells or ameliorating one or more of the symptoms of MPD. Pharmaceutical compositions, single unit dosage forms, and kits suitable for use in methods of the invention are also disclosed. | 2009-01-08 |
20090010887 | Method and composition for enhancing anti-angiogenic therapy - The present invention relates to the surprising discovery that agents that increase intracellular accumulation of NADH+H | 2009-01-08 |
20090010888 | Use of cytochrome P450 reductase as insecticidal target - The invention provides a method of enhancing the effectiveness of pesticides, as well as pesticidal formulations. Furthermore, it also provides the means for the de novo rational design of pesticides. The present invention also relates to a method of screening agents for potential use in insecticides, particularly against mosquitoes. | 2009-01-08 |
20090010889 | Treatment Using Herpes Simplex Virus - The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of said HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed. | 2009-01-08 |
20090010890 | STORAGE STABLE COMPOSITIONS OF BIOLOGICAL MATERIALS - Storage stable compositions of biological materials, including bioactive biological materials are provided in the form of a water-in-oil emulsion, comprising:
| 2009-01-08 |
20090010891 | Sepsis Treatment Agent - To provide a bacterial translocation preventive for humans and animals comprising a probiotics formulation which has lactic acid bacteria, butyric acid bacteria, and saccharifying bacteria as the main components thereof. And to provide a sepsis treatment agent for humans and animals comprising a probiotics formulation which has lactic acid bacteria, butyric acid bacteria, and saccharifying bacteria as the main components thereof. | 2009-01-08 |
20090010892 | Hyperlipidemia Treatment Agent - To provide a cholesterolemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering serum cholesterol. And to provide a triglyceridemia treatment agent comprising, as an active ingredient, a bacterial mixture of three bacterial types consisting of lactic acid bacteria, butyric acid bacteria, and glycation bacteria which are effective in lowering triglycerides. | 2009-01-08 |
20090010893 | Canine probiotic Bifidobacteria globosum - According to the invention there is provided a strain of lactic acid bacteria of the species | 2009-01-08 |
20090010894 | METHODS AND SYSTEMS FOR IDENTIFYING COMPOUNDS THAT MODULATE ALPHA-SYNUCLEIN AGGREGATION - This invention relates to the field of determining the ability of agents to interfere with, reverse, or prevent α-synuclein aggregation and α-synuclein-related pathology and behavior. This invention also relates to methods for screening candidate agents for their potential as human medicaments. | 2009-01-08 |
20090010895 | Isolated cells and populations comprising same for the treatment of CNS diseases - An isolated human cell and populations thereof is provided comprising at least one astrocytic phenotype and at least one mesenchymal stem cell phenotype, wherein the mesenchymal stem cell phenotype is not an astrocytic phenotype. | 2009-01-08 |
20090010896 | METHODS AND COMPOSITIONS FOR OPTIMIZED EXPANSION AND IMPLANTATION OF MESENCHYMAL STEM CELLS - Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (MSCs) to a patient in need of MSCs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets. | 2009-01-08 |
20090010897 | Muscle derived cells for the treatment of cardiac pathologies and methods of making and using the same - The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction. | 2009-01-08 |
20090010898 | Method for treating a mammal having damaged articular cartilage tissue - A method for treating a mammal having damaged articular cartilage tissue includes harvesting a tissue sample from the mammal, growing articular cartilage cells from the tissue sample, and transplanting the articular cartilage cells into the damaged tissue. Growing the articular cartilage cells from the tissue sample can be accomplished by breaking the tissue sample into fragments, placing the fragments into a culture vessel, inducing at least some of the fragments to adhere to the culture vessel, and supplying the fragments with nutrients so that articular cartilage cells contained therein divide and grow. | 2009-01-08 |
20090010899 | Methods related to surgery - The invention is directed to methods related to surgery, for example gastrointestinal surgery. In particular, the invention is methods of treating fistulae, promoting accelerated healing of anastomoses and preventing failure of anastomoses. Such methods utilize novel compositions, including but not limited to extraembryonic cytokine secreting cells (herein referred to as ECS cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), cell lysates derived therefrom, and cell products derived therefrom, each alone or in combination. | 2009-01-08 |
20090010900 | Embryonic Stem Cell Derivatives, and Methods of Making and Using the Same - The presently disclosed subject matter provides embryonic stem (ES) cell derivatives that can be employed in therapeutic methods. Also provided are methods for generating and using the ES cell derivatives. | 2009-01-08 |
20090010901 | PRIMARY CULTURED ADIPOCYTES FOR GENE THERAPY - The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. | 2009-01-08 |
20090010902 | TLR4 Transcription Activity Suppressor - The object of the invention is to provide a TLR4 transcription factor activity suppressor which suppresses TLR4 transcription factor and is effective in inducing or maintaining remission of ulcerative colitis. | 2009-01-08 |
20090010903 | Ferulate Esterase Producing Strains and Methods of Using Same - Ferulate esterase producing bacterial strains or functional mutants thereof and methods of using ferulate esterase producing bacterial strains as forage additives are disclosed. | 2009-01-08 |
20090010904 | Immunostimulating Agent and Method for Production Thereof - The object is to provide: a safe immunomodulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunomodulating agent; and a novel application of a coffee extract residue. Disclosed is an immunomodulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunomodulating effect of the immunomodulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage like strain RAW264 or J774.1, a murine splenocyte, a murine peritoneal macrophage and a murine dendrocyte. A composition containing the immunomodulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition. | 2009-01-08 |
20090010905 | Protection of Plants Against Their Pathogenic Agents - This invention relates compositions and methods for protecting plants against various pathogenic agents such as fungi, viruses and bacteria. The invention can be used alone or in alternation and/or in combination with other plant protection means, and is suitable for the treatment of multiple plant species. | 2009-01-08 |
20090010906 | PERORAL DOSAGE FORMS TO ACHIEVE A SUSTAINED-RELEASE EFFECT AFTER MEDICAMENT DOSAGE WITH A MEAL - The present invention relates a retard formulation for oral administration together with a meal comprising at least one active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipient(s) as well as an amount of an agent being able to form a gas (hereinafter also referred to as gas forming agent or gas former), which gas forming agent achieves a homogeneous mixture of the active pharmaceutical ingredient, hereinafter referred to as API, with the content of the stomach, hence providing a continuous initial absorption phase of the API. | 2009-01-08 |
20090010907 | Dnazymes for Inhibition of Japanese Encephalitis Virus Replication - The present invention relates to synthetic catalytic DNA molecules or DNAzymes which specifically cleave the RNA sequences of the Japanese Encephalitis Viral genome and is useful in treating Japanese Encephalitis infection. The DNAzyme comprises of a chemical modification, a catalytic domain and two hybridizing arms. The DNAzymes are 29-45 nucleotides in length. The 3′ end of the DNAzyme is tethered to a poly-(G) | 2009-01-08 |
20090010908 | Materials and Methods for Diagnosis and Treatment of Chronic Fatigue Syndrome - The invention relates to materials and methods for diagnosis and treatment of chronic fatigue syndrome/myalgic encephalitis. A number of genes are identified which are expressed at abnormal levels in patients affected by CFS/ME as compared to normal healthy individuals. These genes include those encoding defensin α1, haemoglobin γ, CXCR4, tubulin beta 1, serine/threonine kinase 17B, HLA DRss4 and prostaglandin D2 synthase. The genes identified provide objective disease markers that may be used in diagnostic tests to support the diagnosis of CFS/ME or for monitoring the effectiveness of therapy. They also provide a rational basis for classifying CFS/ME patients according to the biochemical lesion underlying their symptoms and enable provision of appropriate targeted therapies. | 2009-01-08 |
20090010909 | Novel GPCR and methods of use of the same - The present invention relates to methods of identifying antagonists of GPR22, a G protein-coupled receptor (GPCR) and related compositions and methods. Antagonists of GPR22 are useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure. | 2009-01-08 |